Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 3

2(50.0%)

4Total

Phase 1(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04593940Phase 3Completed

Immune Modulators for Treating COVID-19

Role: lead

NCT01431326Completed

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Role: lead

NCT00734539Phase 3Completed

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

Role: lead

NCT00797420Phase 1Completed

Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers

Role: lead

NCT01587495Phase 1Terminated

Pharmacokinetics and Safety of Ertapenem in the Postpartum Period

Role: lead

All 5 trials loaded